Adverse Impact of Hepatitis C Virus Infection on Renal Replacement Therapy and Renal Transplant Patients in Australia and New Zealand

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Transplantation

• Publication date

  2010-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/TP.0b013e3181f92548PMID 20861806
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HCV in Patients With End-Stage Renal Disease

  2008cited by this paper
• Effects of Hepatitis C-Induced Liver Fibrosis on Survival in Kidney Transplant Candidates

  2007cited by this paper
• Hepatitis C Virus Infection and Kidney Transplantation: Predictors of Patient and Graft Survival

  2007cited by this paper
• Renal transplantation in patients over 60 years of age: a single-center experience.

  2006cited by this paper
• Meta‐analysis: anti‐viral therapy of hepatitis C virus‐related liver disease in renal transplant patients

  2006cited by this paper
• Special Article: National Surveillance of Dialysis‐Associated Diseases in the United States, 2002

  2005cited by this paper
• Interferon Therapy in Hemodialysis Patients with Chronic Hepatitis C: Study of Tolerance, Efficacy and Post-Transplantation Course

  2005cited by this paper
• Natural History of Hepatitis B and C in Renal Allograft Recipients

  2005cited by this paper
• Natural History of Hepatitis C Virus‐Related Liver Fibrosis After Renal Transplantation

  2005cited by this paper
• Meta‐analysis: effect of hepatitis C virus infection on mortality in dialysis

  2004cited by this paper
• The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure.

  2004cited by this paper
• Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

  2003cited by this paper
• Pretransplant hepatitis C virus infection and its effect on the post‐transplant course of living renal allograft recipients

  2003cited by this paper
• Hepatitis C infection and the patient with end‐stage renal disease

  2002cited by this paper
• Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection.

  2002cited by this paper
• Management of chronic viral hepatitis before and after renal transplantation

  2002cited by this paper
• Characteristics of Hepatitis C in Renal Transplant Candidates

  2002cited by this paper
• Hepatitis C virus infection in renal failure patients in the absence of anti‐hepatitis C virus antibodies

  2002cited by this paper
• Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation

  2002cited by this paper
• Hepatitis C antibody status and outcomes in renal transplant recipients.

  2001cited by this paper
• Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients.

  2001cited by this paper
• Long-term outcome of kidney transplantation in patients with hepatitis C virus infection.

  2001cited by this paper
• Cardiovascular disease in chronic renal failure: the challenge continues. Registro Lombardo Dialisi e Trapianto.

  2000cited by this paper
• Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy.

  2000cited by this paper
• Hepatitis C in dialysis patients in egypt: relationship to dialysis duration, blood transfusion, and liver disease.

  2000cited by this paper
• Impact of hepatitis B and C virus on kidney transplantation outcome

  1999cited by this paper
• Risk of death among chronic dialysis patients infected with hepatitis C virus.

  1998cited by this paper
• Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease1

  1998cited by this paper
• Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group.

  1998cited by this paper
• Demography and survival of patients receiving treatment for chronic renal failure in Australia and New Zealand: report on dialysis and renal transplantation treatment from the Australia and New Zealand Dialysis and Transplant Registry.

  1995cited by this paper
• Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients.

  1993cited by this paper
• Detection of antibody to hepatitis C virus in renal transplant recipients.

  1991cited by this paper
• Detection of antibody to hepatitis C virus in renal transplant recipients.

  1991cited by this paper

• Seroprevalences and factors associated with HBV, HCV and HIV infections in haemodialysis patients in rural areas of Gabon

  2025influential citation
• Outcomes of Dialysis Patients Living With HIV in Australia and New Zealand: A Cohort Study Using the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA)

  2025influential citation
• The Fixed Dose Combination of Sofosbuvir and Velpatasvir is Safe and Effective in Patients of Chronic Hepatitis C With End-stage Renal Disease.

  2024cites this paper
• Real-world effectiveness and safety of direct-acting antivirals for the treatment of hepatitis C virus in kidney and liver transplant recipients: experience of a large transplant center in Brazil

  2023cites this paper
• Newly diagnosed hepatitis C infection after pancreas transplantation with multiple treatment failures

  2023cites this paper
• Current Approach to Renal Transplantation Candidates and Potential Donors with Viral Hepatitis

  2023cites this paper
• Serum Aminotransferases in Chronic Kidney Disease Patients: A Hospital based Comparative Study

  2023cites this paper
• Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China

  2022cites this paper
• Is the Treatment with Direct Acting Antiviral Agents (DAAs) Affecting Glomerular Filtration Rate (GFR)?

  2022cites this paper
• Hepatitis Virus C-associated Nephropathy: A Review and Update

  2022cites this paper
• HCV-positive kidney transplant patients treated with direct-acting antivirals maintain stable medium-term graft function despite persistent reduction in tacrolimus trough levels

  2022cites this paper
• KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

  2022cites this paper
• Propensity Score Modeling in Electronic Health Records with Time-to-Event Endpoints: Application to Kidney Transplantation

  2022cites this paper
• A Review of kidney transplantation from HCV-Viremic Donors into Negative Recipients.

  2021cites this paper
• Impact of Hepatitis C Viral Load in Chronic Kidney Disease Patients‎

  2021cites this paper
• Hepatitis C in Chronic Kidney Disease - An Overview of the KDIGO Guideline.

  2020cites this paper
• Anti-Thymocyte Globulin versus Interleukin-2 Receptor Antagonist in Kidney Transplant Recipients with Hepatitis C Virus.

  2020influential citation
• Hepatitis c virus and chronic kidney disease

  2020cites this paper
• Prevalence and seroconversion of hepatitis C among hemodialysis patients in Assiut governorate, Egypt

  2020cites this paper
• THE RELATIONSHIP OF SERUM AMINOTRANSFERASES WITH SODIUM AND CREATININE AND THEIR ASSOCIATION WITH INTERDIALYTIC WEIGHT GAIN (IDWG)

  2020cites this paper
• EASL recommendations on treatment of hepatitis C - Final update of the series.

  2020cites this paper
• Association Between Serum Albumin Level and All-Cause Mortality in Patients With Chronic Kidney Disease: A Retrospective Cohort Study.

  2020cites this paper
• Tacrolimus Therapeutic Drug Monitoring in Vietnamese Renal Transplant Recipients

  2020cites this paper
• Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals Era.

  2020cites this paper
• Hepatitis C Virus NAT‐Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus–Negative Recipients: A Real‐World Experience

  2020cites this paper
• Occult Hepatitis C Virus Infection among Hemodialysis Patients: An Iranian Experience.

  2020cites this paper
• Effect of Recipient Hepatitis C Status on the Outcome of Deceased Donor Kidney Transplantation.

  2020cites this paper
• Review: Evaluation and Management of the HIV/HCV Co-Infected Kidney or Liver Transplant Candidate

  2020cites this paper
• Sofosbuvir-Velpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney Transplantation.

  2020cites this paper
• Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre‐ and post‐direct‐acting antiviral therapy eras: 10‐Year single center experience

  2019cites this paper
• Detection of Hepatis C Virus-Related Immunologic Markers and Their Impact on Outcomes of Living-Donor Kidney Transplant Recipients.

  2019cites this paper
• Erratum to “Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients”

  2019cites this paper
• Highly effective treatment response and well tolerability by all oral direct acting antivirals for chronic hepatitis C patients post organ transplantation

  2019cites this paper
• Epidemiological and clinical implications in Kidney Transplantation of occult Hepatitis C virus infection

  2019cites this paper
• Hepatitis C and kidney transplant: The eradication time of the virus has arrived

  2019cites this paper
• Hepatitis C and kidney transplant: The eradication time of the virus has arrived.

  2019cites this paper
• Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients

  2019cites this paper
• PREVALENCE AND GENOTYPING OF HEPATITIS C VIRUS IN HEMODIALYSIS PATIENTS AND EVALUATION OF HCV-CORE ANTIGEN TEST IN SCREENING PATIENTS FOR DIALYSIS IN SANA'A CITY, YEMEN

  2019cites this paper
• Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection.

  2019influential citation
• Living Kidney Donation in Individuals with Hepatitis C and HIV Infection: Rationale and Emerging Evidence

  2019cites this paper
• KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

  2019cites this paper
• Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients

  2019cites this paper
• Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors.

  2019cites this paper
• No evidence of occult hepatitis C or E virus infections in liver‐transplant patients with sustained virological response after therapy with direct acting agents

  2019cites this paper
• Hepatitis C virus and mortality among patients on dialysis: A systematic review and meta-analysis.

  2019cites this paper
• Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study

  2019cites this paper
• Prevalence and genotyping of Hepatitis C Virus in hemodialysis patients and evaluation of HCV-Core Antigen Test in screen Dialysis Patients in Sana'a city,

  2019cites this paper
• Non-immunological complications following kidney transplantation

  2019cites this paper
• The Burden of Untreated Hepatitis C Virus Infection in Renal Patients in the United Kingdom

  2018cites this paper
• Hepatitis C treatment in kidney transplant recipients: the need for sustained vigilance after sustained viral response

  2018cites this paper
• Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.

  2018cites this paper
• Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals

  2018cites this paper
• EASL Recommendations on Treatment of Hepatitis C 2018.

  2018cites this paper
• OriginalClinicalScienceçLiver Long-term Patient and Graft Survival of Kidney Transplant Recipients With Hepatitis C Virus Infection in the United States

  2018cites this paper
• Timing of hepatitis C virus infection treatment in kidney transplant candidates

  2018cites this paper
• Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients

  2018cites this paper
• Hepatitis C virus infection in kidney transplantation‐changing paradigms with novel agents

  2018cites this paper
• The Mexican consensus on the treatment of hepatitis C

  2018cites this paper
• Hepatitis C virus infection in chronic kidney disease: paradigm shift in management

  2018influential citation
• Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life

  2018cites this paper
• The long-term impact of hepatitis C infection in kidney transplantation in the pre-direct acting antiviral era.

  2018cites this paper
• Risks, benefits, and ethical questions associated with transplanting kidneys from hepatitis C virus‐infected donors into hepatitis C virus‐negative patients

  2018cites this paper
• Hepatitis C virus and the kidney

  2018cites this paper
• The association of hepatitis C infection with the onset of CKD and progression into ESRD

  2018cites this paper
• Management and treatment of the HCV‐infected kidney transplant patient

  2018cites this paper
• The epidemiology of HCV infection in patients with advanced CKD/ESRD: A global perspective

  2018cites this paper
• KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

  2018cites this paper
• LIJEČENJE PEGILIRANIM INTERFERONOM PRIJE TRANSPLANTACIJE POBOLJŠAVA TRANSPLANTACIJSKI ISHOD U DIJALIZIRANIH BOLESNIKA INFICIRANIH VIRUSOM HEPATITISA C

  2018influential citation
• Management of Hepatitis C Infection in Kidney Transplantation Candidates and Recipients

  2018cites this paper
• The Mexican consensus on the treatment of hepatitis C.

  2018cites this paper
• Extrahepatic Manifestations of Hepatitis C Virus After Liver Transplantation.

  2017cites this paper
• Use of HCV+ Donors Does Not Affect HCV Clearance With Directly Acting Antiviral Therapy But Shortens the Wait Time to Kidney Transplantation

  2017cites this paper
• Posttransplant De Novo Hepatitis C Virus Infection in Renal Transplant Recipients: Its Impact on Morbidity and Mortality.

  2017cites this paper
• The long-term outcomes of hepatitis C virus core antigen-positive Japanese renal allograft recipients

  2017cites this paper
• I nuovi farmaci antivirali per la terapia di HCV post- trapianto renale

  2017cites this paper
• Kidney Transplantation in the Hepatitis C Infected Recipient

  2017cites this paper
• Efficacy and safety of direct-acting antivirals for treatment of hepatitis C infected kidney transplant recipients; a meta-analysis

  2017cites this paper
• Use of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C Virus Infection in the Perspective of Kidney Transplantation

  2017cites this paper
• The influence of deceased kidney donor blood urea nitrogen (BUN) level on graft and patient survival time

  2017cites this paper
• Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients

  2017cites this paper
• Hepatitis C and Its Metabolic Complications in Kidney Disease.

  2017cites this paper
• Malignancies in hepatitis C virus‐positive and ‐negative kidney transplant recipients: A case‐controlled study

  2017cites this paper
• Use of New Direct-Acting Antivirals (DAAs) in Renal Transplant Patients Infected with Hepatitis C Virus: The First Experience in Sub-Saharan Africa

  2017influential citation
• Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection

  2017influential citation
• Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study

  2017influential citation
• Long-term Patient and Graft Survival of Kidney Transplant Recipients With Hepatitis C Virus Infection in the United States

  2017cites this paper
• Post Hepatitis C Cirrhosis in Sub-Sahara Kidney Transplant, Treated with Sofosbuvir/Ledipasvir: Report of Case and Review of Literature

  2017cites this paper
• Hepatitis C infection in renal transplantation: pathogenesis, current impact and emerging trends

  2017cites this paper
• Interferon-Free Therapy for Hepatits C in Brazil and Sustained Virological Response

  2017cites this paper
• Full Reviews An update on the management of hepatitis C virus-infected patients with stage 4–5 chronic kidney disease while awaiting the revised KDIGO Guidelines

  2017cites this paper
• Hepatitis B and C in Kidney Transplantation

  2017cites this paper
• EASL Recommendations on Treatment of Hepatitis C 2016.

  2017cites this paper
• Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct‐Acting Antiviral Agents

  2016cites this paper
• An update on the management of hepatitis C virus-infected patients with stage 4-5 chronic kidney disease while awaiting the revised KDIGO Guidelines.

  2016cites this paper
• SASLT Guidelines: Update in Treatment of Hepatitis C Virus Infection

  2016cites this paper
• Empfehlungen zur antiviralen Therapie der chronischen Hepatitis C bei Patienten auf der Warteliste und nach Transplantation

  2016cites this paper
• Treatment With LedipasvirSofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection

  2016cites this paper
• Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure

  2016cites this paper
• HCV and the kidney

  2016cites this paper
• Outcomes of Lung Transplantation in Recipients With Hepatitis C Virus Infection

  2016cites this paper